BRAF and glioblastoma: For IDH-wide type GBM patients, the mutation of BRAF may benefit them while the co-alteration of EGFR/PTEN/CDKN2A and mutation of PIK3CA and H3K27M correlates with worse clinical outcomes (Mirchia and Richardson, 2020; Umehara et al., 2019).